Press Release Archives — Zymeworks
Zymeworks Inc. Aktie News
Press Release Archives — Zymeworks
Zymeworks Inc.: Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware - Form 8-K - MoneyController (ID 827317)
Zymeworks Announces Appointment of Biotech and Pharmaceutical Leader Derek J. Miller to its Board of Directors | T-Net News
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital | ZYME Stock News
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani | Business Wire
ZYME - Zymeworks Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGS)
Press Release Archives — Zymeworks
Zymeworks Raises $80 Million in Initial Public Offering (IPO) on Toronto and New York Stock Exchanges | T-Net News
Jazz opts in to Zymeworks HER2 drug for $325m upfront | pharmaphorum
425
Zymeworks Reports 2019 First Quarter Financial Results - Lumira News
Zymeworks Inc. on LinkedIn: #jpm2024
Zymeworks Inc. on LinkedIn: Today we announced our third quarter 2023 financial results. Join us for a…
Zymeworks Announces $50 Million Private Placement to EcoR1
SEC Filing | Zymeworks Inc.
News — Page 6 of 6 — Zymeworks
Zymeworks Inc. on X: "Today we announced topline results from the pivotal Phase 2b HERIZON-BTC-01 clinical trial investigating our HER2-targeted bispecific antibody in patients with previously treated HER2-amplified & expressing #biliarytract cancer (
Acadian Asset Management LLC Acquires 727,934 Shares of Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress | Zymeworks Inc.
Zymeworks Reports 2021 First Quarter Financial Results | Zymeworks Inc.
Press Release Archives — Zymeworks
Zymeworks Inc. on LinkedIn: #immunology
Press Release Archives — Zymeworks
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting | BioSpace
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer | Zymeworks Inc.
Zymeworks Corporate Presentation
